The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Granulomatosis with Polyangiitis Drug Market Research Report 2025
Synopsis
The global Granulomatosis with Polyangiitis Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Granulomatosis with Polyangiitis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Granulomatosis with Polyangiitis Drug.
Report Scope
The Granulomatosis with Polyangiitis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Granulomatosis with Polyangiitis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Granulomatosis with Polyangiitis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium
Segment by Type
Benralizumab
Avacopan
Rituximab Biosimilar
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Granulomatosis with Polyangiitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Granulomatosis with Polyangiitis Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Granulomatosis with Polyangiitis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Granulomatosis with Polyangiitis Drug.
Report Scope
The Granulomatosis with Polyangiitis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Granulomatosis with Polyangiitis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Granulomatosis with Polyangiitis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium
Segment by Type
Benralizumab
Avacopan
Rituximab Biosimilar
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Granulomatosis with Polyangiitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Granulomatosis with Polyangiitis Drug Market Overview
1.1 Product Overview and Scope of Granulomatosis with Polyangiitis Drug
1.2 Granulomatosis with Polyangiitis Drug Segment by Type
1.2.1 Global Granulomatosis with Polyangiitis Drug Market Value Comparison by Type (2024-2030)
1.2.2 Benralizumab
1.2.3 Avacopan
1.2.4 Rituximab Biosimilar
1.2.5 Others
1.3 Granulomatosis with Polyangiitis Drug Segment by Application
1.3.1 Global Granulomatosis with Polyangiitis Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Granulomatosis with Polyangiitis Drug Market Size Estimates and Forecasts
1.4.1 Global Granulomatosis with Polyangiitis Drug Revenue 2019-2030
1.4.2 Global Granulomatosis with Polyangiitis Drug Sales 2019-2030
1.4.3 Global Granulomatosis with Polyangiitis Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Granulomatosis with Polyangiitis Drug Market Competition by Manufacturers
2.1 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Granulomatosis with Polyangiitis Drug Average Price by Manufacturers (2019-2024)
2.4 Global Granulomatosis with Polyangiitis Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Granulomatosis with Polyangiitis Drug, Product Type & Application
2.7 Granulomatosis with Polyangiitis Drug Market Competitive Situation and Trends
2.7.1 Granulomatosis with Polyangiitis Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Granulomatosis with Polyangiitis Drug Players Market Share by Revenue
2.7.3 Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Granulomatosis with Polyangiitis Drug Retrospective Market Scenario by Region
3.1 Global Granulomatosis with Polyangiitis Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Granulomatosis with Polyangiitis Drug Global Granulomatosis with Polyangiitis Drug Sales by Region: 2019-2030
3.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2019-2024
3.2.2 Global Granulomatosis with Polyangiitis Drug Sales by Region: 2025-2030
3.3 Global Granulomatosis with Polyangiitis Drug Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2019-2030
3.3.1 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2019-2024
3.3.2 Global Granulomatosis with Polyangiitis Drug Revenue by Region: 2025-2030
3.4 North America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.4.1 North America Granulomatosis with Polyangiitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Granulomatosis with Polyangiitis Drug Sales by Country (2019-2030)
3.4.3 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.5.1 Europe Granulomatosis with Polyangiitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2019-2030)
3.5.3 Europe Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.7.1 Latin America Granulomatosis with Polyangiitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2019-2030)
3.7.3 Latin America Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2019-2030)
4.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2019-2024)
4.1.2 Global Granulomatosis with Polyangiitis Drug Sales by Type (2025-2030)
4.1.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2019-2030)
4.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2019-2030)
4.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2019-2024)
4.2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2025-2030)
4.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2019-2030)
4.3 Global Granulomatosis with Polyangiitis Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2019-2030)
5.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2019-2024)
5.1.2 Global Granulomatosis with Polyangiitis Drug Sales by Application (2025-2030)
5.1.3 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2019-2030)
5.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2019-2030)
5.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2019-2024)
5.2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2025-2030)
5.2.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2019-2030)
5.3 Global Granulomatosis with Polyangiitis Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bionovis SA
6.1.1 Bionovis SA Corporation Information
6.1.2 Bionovis SA Description and Business Overview
6.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
6.1.5 Bionovis SA Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 ChemoCentryx Inc
6.3.1 ChemoCentryx Inc Corporation Information
6.3.2 ChemoCentryx Inc Description and Business Overview
6.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
6.3.5 ChemoCentryx Inc Recent Developments/Updates
6.4 Coherus BioSciences Inc
6.4.1 Coherus BioSciences Inc Corporation Information
6.4.2 Coherus BioSciences Inc Description and Business Overview
6.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
6.4.5 Coherus BioSciences Inc Recent Developments/Updates
6.5 Genor BioPharma Co Ltd
6.5.1 Genor BioPharma Co Ltd Corporation Information
6.5.2 Genor BioPharma Co Ltd Description and Business Overview
6.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
6.5.5 Genor BioPharma Co Ltd Recent Developments/Updates
6.6 GlaxoSmithKline Plc
6.6.1 GlaxoSmithKline Plc Corporation Information
6.6.2 GlaxoSmithKline Plc Description and Business Overview
6.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
6.6.5 GlaxoSmithKline Plc Recent Developments/Updates
6.7 Iltoo Pharma
6.6.1 Iltoo Pharma Corporation Information
6.6.2 Iltoo Pharma Description and Business Overview
6.6.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
6.7.5 Iltoo Pharma Recent Developments/Updates
6.8 Panacea Biotec Ltd
6.8.1 Panacea Biotec Ltd Corporation Information
6.8.2 Panacea Biotec Ltd Description and Business Overview
6.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
6.8.5 Panacea Biotec Ltd Recent Developments/Updates
6.9 Sandoz International GmbH
6.9.1 Sandoz International GmbH Corporation Information
6.9.2 Sandoz International GmbH Description and Business Overview
6.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
6.9.5 Sandoz International GmbH Recent Developments/Updates
6.10 The International Biotechnology Center (IBC) Generium
6.10.1 The International Biotechnology Center (IBC) Generium Corporation Information
6.10.2 The International Biotechnology Center (IBC) Generium Description and Business Overview
6.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
6.10.5 The International Biotechnology Center (IBC) Generium Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Granulomatosis with Polyangiitis Drug Industry Chain Analysis
7.2 Granulomatosis with Polyangiitis Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Granulomatosis with Polyangiitis Drug Production Mode & Process
7.4 Granulomatosis with Polyangiitis Drug Sales and Marketing
7.4.1 Granulomatosis with Polyangiitis Drug Sales Channels
7.4.2 Granulomatosis with Polyangiitis Drug Distributors
7.5 Granulomatosis with Polyangiitis Drug Customers
8 Granulomatosis with Polyangiitis Drug Market Dynamics
8.1 Granulomatosis with Polyangiitis Drug Industry Trends
8.2 Granulomatosis with Polyangiitis Drug Market Drivers
8.3 Granulomatosis with Polyangiitis Drug Market Challenges
8.4 Granulomatosis with Polyangiitis Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
